Low-molecular-weight heparin (LMWH) is an anticoagulant used in VTE prophylaxis and management, and in the management of ACS.
LMWH is derived from unfractionated heparin (UFH), but does not require APTT monitoring and has more predictable pharmacokinetics (with a longer half-life) and anticoagulant effect. LMWH less commonly causes heparin-induced thrombocytopenia than UFH.